Literature DB >> 19233775

Hot topic: Changes in angiotensin-converting enzyme inhibition and concentrations of the tripeptides Val-Pro-Pro and Ile-Pro-Pro during ripening of different Swiss cheese varieties.

J Meyer1, U Bütikofer, B Walther, D Wechsler, R Sieber.   

Abstract

The angiotensin-converting enzyme (ACE) inhibitory activity and the concentration of the 2 ACE-inhibiting tripeptides Val-Pro-Pro (VPP) and Ile-Pro-Pro (IPP) were studied during cheese ripening in 7 Swiss cheese varieties. The semi-hard cheeses Tilsiter, Appenzeller 1/4 fat, Tête de Moine, and Vacherin fribourgeois and the extra-hard and hard cheeses Berner Hobelkäse, Le Gruyère, and Emmentaler were investigated. Three loaves of each variety manufactured in different cheese factories were purchased at the beginning of commercial ripeness and investigated at constant intervals until the end of the usual sale period. Good agreement was found between ACE-inhibitory activity and the total concentration of VPP and IPP at advanced ripening stages. In most of the investigated varieties ACE-inhibitory activity and the concentration of the 2 tripeptides initially increased during the study period. A decline in the concentration of VPP and IPP was obtained toward the end of the investigated period for Tilsiter and Gruyère. The ratio of VPP/IPP decreased during ripening in all varieties with the exception of Emmentaler. However, large variations were observed among the cheese varieties as well as the individual loaves of the same variety. Chemical characterization of the investigated cheeses revealed that qualitative differences in the proteolysis pattern, not quantitative differences in the degree of proteolysis, are responsible for the observed variations in the concentrations of VPP and IPP. The presence of Lactobacillus helveticus in the starter culture was associated with elevated concentrations of VPP and IPP. The results of the present study show that concentrations of VPP and IPP above 100 mg/kg are attainable in semi-hard cheese varieties after ripening periods of about 4 to 7 mo and that stable concentrations of the 2 antihypertensive tripeptides can be expected over several weeks of cheese ripening.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19233775     DOI: 10.3168/jds.2008-1531

Source DB:  PubMed          Journal:  J Dairy Sci        ISSN: 0022-0302            Impact factor:   4.034


  6 in total

1.  Prolyl aminopeptidase from Streptomyces thermoluteus subsp. fuscus strain NBRC14270 and synthesis of proline-containing peptides by its S144C variant.

Authors:  Yukihiro Yamamoto; Hirokazu Usuki; Masaki Iwabuchi; Tadashi Hatanaka
Journal:  Appl Environ Microbiol       Date:  2010-07-30       Impact factor: 4.792

2.  Milk casein-derived tripeptides, VPP and IPP induced NO production in cultured endothelial cells and endothelium-dependent relaxation of isolated aortic rings.

Authors:  Tatsuhiko Hirota; Atsuko Nonaka; Akiko Matsushita; Naoto Uchida; Kohji Ohki; Masanori Asakura; Masafumi Kitakaze
Journal:  Heart Vessels       Date:  2011-01-08       Impact factor: 2.037

Review 3.  Antihypertensive Peptides from Milk Proteins.

Authors:  Pauliina Jäkälä; Heikki Vapaatalo
Journal:  Pharmaceuticals (Basel)       Date:  2010-01-19

Review 4.  Therapeutic and biotechnological applications of substrate specific microbial aminopeptidases.

Authors:  Arya Nandan; Kesavan Madhavan Nampoothiri
Journal:  Appl Microbiol Biotechnol       Date:  2020-04-28       Impact factor: 4.813

5.  A Novel Angiotensin I-Converting Enzyme Inhibitory Peptide Derived From Goat Milk Casein Hydrolysate Modulates Angiotensin II-Stimulated Effects on Vascular Smooth Muscle Cells.

Authors:  Zijiao Qiao; Jiaqi Wang; Zeqi He; Lina Pan; Konglong Feng; Xiaoyu Peng; Qianru Lin; Yu Gao; Mingyue Song; Sufang Cao; Yunjiao Chen; Yong Cao; Guo Liu
Journal:  Front Nutr       Date:  2022-04-11

Review 6.  Functional Properties of Microorganisms in Fermented Foods.

Authors:  Jyoti P Tamang; Dong-Hwa Shin; Su-Jin Jung; Soo-Wan Chae
Journal:  Front Microbiol       Date:  2016-04-26       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.